Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

Nancy Lin, MD
Published: Friday, Dec 13, 2019



Nancy Lin, MD, discusses the impact of neratinib (Nerlynx) on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer.

This analysis presented at the 2019 San Antonio Breast Cancer Symposium pulled together CNS data from the NALA, NEfERT-T, and TBCRC 022 trials, explains Lin. The phase III NALA trial comparing lapatinib (Tykerb) plus capecitabine versus neratinib plus capecitabine in patients with HER2-positive, pretreated, metastatic breast cancer. The NEfERT-T trial compared first-line neratinib plus paclitaxel versus trastuzumab paclitaxel in HER2-positive metastatic breast cancer. Finally, the TBCRC 022 trial was a single-arm multi-cohort study specifically enrolling patients with progressive CNS disease. In that study, the primary endpoint was CNS objective response.

The goal of analyzing the data from these 3 trials was to compile the CNS-focused data in 1 place, focusing on CNS progression and response, concludes Lin.

<<< View more from 2019 San Antonio Breast Cancer Symposium


Nancy Lin, MD, discusses the impact of neratinib (Nerlynx) on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer.

This analysis presented at the 2019 San Antonio Breast Cancer Symposium pulled together CNS data from the NALA, NEfERT-T, and TBCRC 022 trials, explains Lin. The phase III NALA trial comparing lapatinib (Tykerb) plus capecitabine versus neratinib plus capecitabine in patients with HER2-positive, pretreated, metastatic breast cancer. The NEfERT-T trial compared first-line neratinib plus paclitaxel versus trastuzumab paclitaxel in HER2-positive metastatic breast cancer. Finally, the TBCRC 022 trial was a single-arm multi-cohort study specifically enrolling patients with progressive CNS disease. In that study, the primary endpoint was CNS objective response.

The goal of analyzing the data from these 3 trials was to compile the CNS-focused data in 1 place, focusing on CNS progression and response, concludes Lin.

<<< View more from 2019 San Antonio Breast Cancer Symposium

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x